{
    "clinical_study": {
        "@rank": "92469", 
        "arm_group": [
            {
                "arm_group_label": "Ferric Carboxymaltose (FCM)", 
                "description": "Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician."
            }, 
            {
                "arm_group_label": "Iron Sucrose", 
                "description": "Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician"
            }, 
            {
                "arm_group_label": "Iron Dextran", 
                "description": "Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician"
            }, 
            {
                "arm_group_label": "Ferumoxytol", 
                "description": "Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare the total costs to sites and payers of\n      administering IV iron over the 30-day observation period for subjects with IDA who receive\n      Ferric Carboxymaltose (FCM) relative to those who receive iron sucrose, iron dextran, and\n      ferumoxytol."
        }, 
        "brief_title": "Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Iron Deficiency Anemia (IDA)", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Deficiency Diseases", 
                "Anemia, Iron-Deficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to compare the total costs to sites and payers of\n      administering IV iron over the 30-day observation period for subjects with IDA who receive\n      Ferric Carboxymaltose (FCM) relative to those who receive iron sucrose, iron dextran, and\n      ferumoxytol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must present for the first dose of a current cycle of IV treatment for IDA\n\n          -  Must be over 18 years of age\n\n          -  Must be willing and able to provide informed consent, including permission to obtain\n             information from their medical records.\n\n          -  Must be able to read and understand English.\n\n        Exclusion Criteria:\n\n          -  Subjects not diagnosed with IDA.\n\n          -  Subjects requiring more than one treatment cycle within 30 days.\n\n          -  Subjects receiving maintenance IV iron therapy.\n\n          -  Subjects treated with IV iron within the 30-day period prior to study enrollment.\n\n          -  Subjects who received investigational medication in the six months prior to the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects presenting for IDA treatment"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984554", 
            "org_study_id": "1VIT13033"
        }, 
        "intervention_browse": {
            "mesh_term": "Iron"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "contact": {
                "email": "tkoch@lpicrd.com", 
                "last_name": "Todd Koch", 
                "phone": "610-650-4200"
            }, 
            "contact_backup": {
                "email": "mtokars@lpicrd.com", 
                "last_name": "Marc Tokars", 
                "phone": "610-650-4200"
            }, 
            "facility": {
                "address": {
                    "city": "Norristown", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19403"
                }, 
                "name": "Luitpold Pharmaceuticals, Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "4", 
        "official_title": "Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia", 
        "overall_contact": {
            "email": "tkoch@lpicrd.com", 
            "last_name": "Todd Koch", 
            "phone": "610-650-4200"
        }, 
        "overall_contact_backup": {
            "email": "mtokars@lpicrd.com", 
            "last_name": "Marc Tokars", 
            "phone": "610-650-4200"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Site costs of administering IV iron to subjects to be assessed by applying unit costs to information collected directly on the eCRF (electronic Case Report Form).", 
            "safety_issue": "No", 
            "time_frame": "30 day observation period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984554"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Luitpold Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Luitpold Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}